Audrey Baker

Title: Audrey Baker - Innovator in Oncology Therapeutics

Introduction

Audrey Baker is a prominent inventor based in Philadelphia, PA (US). She has made significant contributions to the field of oncology through her innovative research and development of therapeutic agents. With a focus on peptides that target specific integrins, her work has the potential to advance cancer treatment options.

Latest Patents

Audrey Baker holds a patent for "Peptides antagonistic to an anti-angiogenic antibody and uses therefor." This invention concerns antagonists of alphav-containing integrins, which exhibit therapeutic activity in oncology applications. The methods she developed for selecting such antagonists utilize a peptide that competes for alphaV-integrin binding with a known monoclonal antibody that has demonstrated anti-tumor activity. The claimed peptide represents a conformational epitope or mimotope present on the ligand to which the therapeutic antibodies selectively bind.

Career Highlights

Audrey Baker is currently employed at Centocor, Inc., where she continues to push the boundaries of cancer research. Her work has garnered attention for its innovative approach to targeting integrins, which are crucial in tumor growth and metastasis.

Collaborations

Audrey collaborates with notable colleagues, including David J. Shealy and Sam Wu, who contribute to her research efforts and enhance the impact of her work in the field.

Conclusion

Audrey Baker's contributions to oncology through her patented inventions and collaborative efforts highlight her role as a leading innovator in the field. Her work promises to pave the way for new therapeutic strategies in cancer treatment.